Chelsie Derman is an associate editor for HCPLive who covers allergy and psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.
She can be reached at [email protected].
Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.
The study did not find an association between glycemic parameters and flow-mediated dilation, but they did find associations between lower sleep efficiency with poorer glycemic control, insulin resistance, estimated glucose disposal rate, and HbA1C.
In an interview with HCPLive, Rishi Kakar, MD, discussed how KarXT is a novel molecule unique from currently available schizophrenia treatments.
The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.
By 2040, the number of blindness and vision loss cases are estimated to increase by roughly 50% across Brazil, Russia, India, China, and South America, a new study found.
The FDA issued a warning about the DreamStation 2 CPAP Machine, which is used to treat obstructive sleep apnea, due to reports of the device overheating and leading to fires, smoke, and burns.
Of 1023 color fundus photograph images, the 5 optometrists in the study were able to accuracy diagnosis 226 images with AMD.
In a new study, the highest socioeconomic group was associated with lower morality rates for all-cause mortality, lower morality from natural causes, and higher mortality from external causes. Although the data does not show a significant link between the role of socioeconomic position with the mortality rate among people with mental disorders.
From 2018 to 2021, the deaths among U.S. pregnant and postpartum women aged 35 – 44 years old more than tripled, a new study found.
A new study found a 35% prevalence of newly diagnosed obstructive sleep apnea in patients with lingering COVID-19 symptoms of fatigue or sleepiness.
At the 14-year follow-up, ADHD medication use was associated with a 4% increased risk of cardiovascular diseases.
After receiving the COVID-19 vaccination, the antibody titers of patients with cirrhosis and hepatocellular carcinoma were significantly reduced compared to patients with chronic hepatitis C patients.
Hepatitis B virus vaccination effective for patients with chronic hepatitis C, nonalcoholic liver disease, and liver cirrhosis to significantly improve survival rates.
Standard-Field Fundus Camera performs well in detecting proliferative sickle cell retinopathy, but performs poorly detecting non-proliferative sickle cell retinopathy, a new study found.
After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.
Only the states California, Delaware, Nevada, New Jersey, Oregon, and Pennsylvania require physicians to report medically impaired drivers, and 66% of states reported there was instructions on reporting available on DMV websites.
In the new study, 71% of the patients who developed gross hematuria after a COVID-19 vaccination were females, and for 92% of the patients, the investigators observed gross hematuria had developed after the second or subsequent vaccinations.
Part 1 of the study evaluates reduction in urine protein: creatinine ratio, and part 2 of the study evaluates the number of patients achieving complete remission when on the bruton tyrosine kinase inhibitor for primary membranous nephropathy.
The ravulizumab group had a proteinuria reduction of 40.3% while the placebo group had a reduction of 10.9% by week 26, highlighting ravulizumab’s effectiveness in treating patients with IgA Nephropathy.
Children of mothers in minority group were associated with a higher likelihood of ASD diagnosis, but only children of White mothers had ASD associated with neighborhood disadvantages.
On November 15, 2023, the FDA approved Defencath. The new drug can reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter.
An artificial intelligence can detect increased fluid in lungs by simply hearing voice changes over time—and the increased fluid in lungs can be a sign of heart failure.
Compared to their usual diet, participants placed in the low sodium diet group—required to keep their sodium intake to 500 mg daily—had their blood pressure reduced by 6 mm Hg.
FDA approved sotaglifozin (INPEFA®) on May 26, 2023, to treat heart failure. Also, a phase 3 trial shows the clinical benefits of the drug by the 3-month mark.
Early control of blood pressure helps lower blood pressure levels in postpartum women and potentially slows the progression of needing treatment for hypertension later down the line.
Participants with heart failure measured lower on physical and mental component scores than patients with lung, colon, breast, or prostate cancer, highlighting their worser health-related quality of life.
The incidence of hypertensive disorders of pregnancy rose from 9.22% in January 2018 to 12.15% in December 2021.
Presented at AAO 2023, Kendra Klein-Mascia, MD, discussed her team’s study, comparing faricimab with aflibercept. The study found 2 injections of faricimab gets rid of 75% of retina fluid by week 8, but for aflibercept, erasing the same amount of fluid takes 3 injections until week 12.
At the end of year 2, 80% of patients on faricimab reached > q12 week dosing, and 63% achieved q16 dosing.
A study followed a neonatal cohort with sickle cell disease for up to 20 years. The study demonstrated how hydroxyurea lowers the risk of high mortality.
